|
|
(26 intermediate revisions by 6 users not shown) |
Line 28: |
Line 28: |
| | | |
| <style> | | <style> |
| + | |
| + | /*This Part for Cleaning Default Template*/ |
| + | |
| + | #home_logo, #sideMenu { display:none; } |
| + | html{width:100%;height:100%;background:white; list-style:none;} |
| + | #globalWrapper,#HQ_page,#bodyContent,#mw-content-text{height:100%;} |
| + | #sideMenu, #top_title, .patrollink {display:none;} |
| + | #content { margin-left:0px; margin-top:-7px; padding:0px; width:100%;height:100%;} |
| + | body {background-color:white;height:100%;} |
| + | #bodyContent h1, #bodyContent h2, #bodyContent h3, #bodyContent h4, #bodyContent h5 { margin-bottom: 0px; } |
| + | |
| + | @font-face{ |
| + | font-family: 'DIN B'; |
| + | src: url('https://static.igem.org/mediawiki/2019/f/f5/T--Jilin_China--Home--Font--Medium.otf'); |
| + | font-weight: normal; |
| + | font-size: normal; |
| + | } |
| + | |
| + | @font-face{ |
| + | font-family: 'DIN B'; |
| + | src: url('https://static.igem.org/mediawiki/2019/9/90/T--Jilin_China--Home--Font--Bold.otf'); |
| + | font-weight: Bold; |
| + | font-size: normal; |
| + | } |
| + | |
| + | h1,h2,h3,h4,h5,p{ |
| + | font-family:'DIN B','DIN Medium'; |
| + | } |
| + | h1, h2, h3, h4, h5, h6{ |
| + | overflow:auto !important; |
| + | padding: 1rem 0 !important; |
| + | } |
| + | p{ |
| + | margin:0 !important; |
| + | } |
| html, | | html, |
| body, | | body, |
Line 173: |
Line 208: |
| @media (min-width:1000px) { | | @media (min-width:1000px) { |
| section{ | | section{ |
− | font-family: 'DIN Alternate';
| |
| line-height: 200%; | | line-height: 200%; |
| } | | } |
Line 188: |
Line 222: |
| p{ | | p{ |
| width: 100%; | | width: 100%; |
− | height: auto; | + | height: auto;1 |
| margin: 0 auto; | | margin: 0 auto; |
| position: relative; | | position: relative; |
Line 437: |
Line 471: |
| | | |
| .symptom .digits .digit{ | | .symptom .digits .digit{ |
− | font-size:6.5vw; | + | font-size:5.5vw; |
| margin:0; | | margin:0; |
| } | | } |
Line 567: |
Line 601: |
| <h1 class="bg-white">What's VVC?</h1> | | <h1 class="bg-white">What's VVC?</h1> |
| <p>Vulvovaginal candidiasis (VVC) has been recognized as one of the most common infections in female reproductive organs. </p> | | <p>Vulvovaginal candidiasis (VVC) has been recognized as one of the most common infections in female reproductive organs. </p> |
− | <p>VVC is mainly caused by Candida albicans (C. albicans), accounting for more than 85% of the incidence, which seriously affects the normal life of women.</p> | + | <p>VVC is mainly caused by <em>Candida albicans (C. albicans)</em>, accounting for more than 85% of the incidence, which seriously affects the normal life of women.</p> |
| </div> | | </div> |
| <div class="clear"></div> | | <div class="clear"></div> |
Line 630: |
Line 664: |
| | | |
| <div class="theraputic"> | | <div class="theraputic"> |
− | <h2>Theraputic System</h2> | + | <h2>Therapeutic System</h2> |
| <div> | | <div> |
− | <div class="effector1"><p>LL37 can perforate the cell membrane of C.albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/2/2e/T--Jilin_China--Main--LL37.svg"/></div> | + | <div class="effector1"><p>LL-37 can perforate the cell membrane of C. albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/2/2e/T--Jilin_China--Main--LL37.svg"/></div> |
| <div class="effector2"><p>The β-1,3-glucanase can disrupt the </br>biofilm of C. albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/3/32/T--Jilin_China--Main--beta-1%EF%BC%8C3-glu.svg"/></div> | | <div class="effector2"><p>The β-1,3-glucanase can disrupt the </br>biofilm of C. albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/3/32/T--Jilin_China--Main--beta-1%EF%BC%8C3-glu.svg"/></div> |
| <div class="effector3"><p>BDSF can inhibit hypha formation </br>by C. albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/e/ed/T--Jilin_China--Main--BDSF.svg"/></div> | | <div class="effector3"><p>BDSF can inhibit hypha formation </br>by C. albicans.</p><img alt="" src="https://static.igem.org/mediawiki/2019/e/ed/T--Jilin_China--Main--BDSF.svg"/></div> |
Line 652: |
Line 686: |
| <div class="third_s"> | | <div class="third_s"> |
| <div id="third_1"> | | <div id="third_1"> |
− | | + | <div style="padding: 7.5vw"><img src="https://static.igem.org/mediawiki/2019/b/bc/T--Jilin_China--HP--HP_Overview.svg" width="100%" style=" margin: 0 auto"></div> |
− | <div class="t1inb"><div class="t1nb0"><img class="yilei" src="https://static.igem.org/mediawiki/2019/9/96/T--Jilin_China--Main--HP_Brain_Half.svg" width="60%" ></div><div class="t1nb1"><div class="t1nb11">Initially, we brainstormed to decide our project. We came up with three projects: General White Resistance, Vaginitis Treatment and Plant Resistance Improvement</div></div></div>
| + | |
− | | + | |
− | <div class="t1inb "><div class="t1nb0"><img class="erlei" class="imgdo" src="https://static.igem.org/mediawiki/2019/c/c7/T--Jilin_China--Main--HPwomen.svg" height="90%" ></div><div class="t1nb1 t1do"><div class="t1nb11">After attending the women's lecture, we decided to study the method of treating vaginitis and confirmed VVC through questionnaire collection.</div></div></div>
| + | |
− | | + | |
− | <div class="t1inb"><div class="t1nb0"><img class="yilei" src="https://static.igem.org/mediawiki/2019/3/3a/T--Jilin_China--Main--HP_Brain_Full.svg" width="60%" ></div><div class="t1nb1"><div class="t1nb11">After interviewing patients and doctors, we learned about the current problems in the treatment of VVC and brainstormed the project 1.0.</div></div></div>
| + | |
− | | + | |
− | <div class="t1inb "><div class="t1nb0"><img class="sanlei aha" src="https://static.igem.org/mediawiki/2019/5/5d/T--Jilin_China--Main--HP1.0.svg" width="45%" ></div><div class="t1nb1 t1do"><div class="t1nb11">After having brainstormed project 1.0.We interviewed professors give us suggestions to improve our project 1.0 and obtained project 2.0.</div></div></div>
| + | |
− | | + | |
− | <div class="t1inb"><div class="t1nb0"><img class="sanlei" src="https://static.igem.org/mediawiki/2019/7/72/T--Jilin_China--Main--HP2.0.svg" width="45%" ></div><div class="t1nb1"><div class="t1nb11"> We interviewed experts for a comprehensive assessment of our project. To make project practical, we interviewed ethical experts, pharmacies and pharmacies.</div></div></div>
| + | |
− | <div id="hparrow"><img src="https://static.igem.org/mediawiki/2019/c/c7/T--Jilin_China--Main--HP_arrow.svg" width="130%"></div></div>
| + | |
| </div> | | </div> |
| | | |
Line 720: |
Line 744: |
| <div id="result" class="botton otr"><p>Result</p><a class="foota otr1" href="https://2019.igem.org/Result"></a></div> | | <div id="result" class="botton otr"><p>Result</p><a class="foota otr1" href="https://2019.igem.org/Result"></a></div> |
| | | |
− | <div id="par" class="botton otr"><p>Our Parts</p><a class="foota otr1" href="https://2019.igem.org/Team:Jilin_China/Parts"></a></div> | + | <div id="par" class="botton otr"><p>Parts</p><a class="foota otr1" href="https://2019.igem.org/Team:Jilin_China/Parts"></a></div> |
| | | |
| <div id="hpp" class="botton otr"><p>Practices</p><a class="foota otr1" href="https://2019.igem.org/Team:Jilin_China/Human_Practices"></a></div> | | <div id="hpp" class="botton otr"><p>Practices</p><a class="foota otr1" href="https://2019.igem.org/Team:Jilin_China/Human_Practices"></a></div> |
Line 802: |
Line 826: |
| </script> | | </script> |
| </html> | | </html> |
− | {{:Team:Jilin_China/foot_cont}} | + | {{:Team:Jilin_China/foot_Cont}} |